Pernix Therapeutics Revenue, Profits - PTX Quarterly Income Statement

Add to My Stocks
$2.43 $0.01 (0.41%) PTX stock closing price Jun 21, 2018 (Closing)

PTX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Pernix Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 41.54M to 28.14M and how operating and non operating activities have impacted the PTX stock. Revenue for year 2018 Q1 is $28.14M and has decreased from $41.54M quarter on quarter as is evident when you compare the latest figures in the latest Pernix Therapeutics profit and loss statement with those of the prior corresponding period. Also see Pernix Therapeutics assets and Pernix Therapeutics free cash flow for a complete valuation of PTX stock.

View and download details of revenue and profits for Pernix Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Pernix Therapeutics Revenues or Net Sales
28.14M41.54M40.47M34.32M29.74M30.17M41.47M36.75M32.47M46.37M
Cost Of Goods Sold (COGS)8.96M13.52M10.58M10.49M10.04M9.06M10.84M12.19M11.23M14.51M
Pernix Therapeutics Gross Profit
19.17M28.03M29.88M23.82M19.7M21.13M30.62M24.55M21.23M31.88M
Research & Development Expense------1.71M2.49M-2.58M
Selling General & Admin Expense18.37M34.45M10.56M18.16M20.72M76.3M25.61M23.29M20.44M51.93M
Income Before Depreciation Depletion Amortization--6.5M19.22M5.57M-1.54M-56.11M3.29M-1.23M-0.14M-22.62M
Depreciation Depletion Amortization9.86M18.25M18.21M18.21M18.54M20.71M20.7M21.06M23.66M28.21M
Non Operating Income-0.01M2.03M14.69M--0.35M2.19M-0.17M-6.93M-0.67M
Interest Expense9.46M9.48M9.32M9.2M8.95M11.05M8.85M8.93M9.02M9.28M
Pernix Therapeutics Pretax Income
-18.54M-32.17M6.38M-21.57M-29.4M-85.68M-26.43M-31.14M-25.9M-60.8M
Provision for Income Taxes--------0.01M-20.87M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-18.58M-32.42M6.36M-21.62M-29.46M-86.08M-26.44M-31.14M-25.94M-81.67M
Extraordinary Items & Discontinued Operations----------
Pernix Therapeutics Profit/ Loss (Net Income)
-18.58M-32.42M6.36M-21.62M-29.46M-86.08M-26.44M-31.14M-25.94M-81.67M
Average Shares used to compute Diluted EPS11.87M11.66M16.52M10.02M10.02M7.83M8.84M6.67M6.11M6.11M
Average Shares used to compute Basic EPS11.87M11.66M11.12M10.02M10.02M7.83M8.84M6.67M6.11M6.11M
Income Before Nonrecurring Items-18.58M-32.42M-9.97M-21.62M-29.46M-37.21M-24.16M-32.57M-21.52M-36.01M
Income from Nonrecurring Items--16.33M---48.87M-2.28M1.43M-4.42M-45.66M
Pernix Therapeutics Earnings Per Share Basic Net
-1.57-2.780.57-2.16-2.94-10.10-2.99-4.70-4.20-13.40
Pernix Therapeutics Earnings Per Share Diluted Net
-1.57-2.780.42-2.16-2.94-10.10-2.99-4.70-4.20-13.40
EPS Diluted Before Nonrecurring Items-1.57-2.78-0.57-2.16-2.94-3.86-2.73-4.90-3.50-5.90
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Pernix Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $28.14M for this quarter of 2018 Q1. Our Pernix Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-18.58M for Pernix Therapeutics for 2018 Q1. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the PTX income statement, one can check the Pernix Therapeutics historical stock prices to check how the price has moved with time.

Pernix Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
0.2
Dividend Yield
0%